壳聚糖碘治疗CINⅠ伴高危HPV感染的疗效观察

Clinical efficacy of Chitosan-iodine in treatment of CINⅠ with high-risk human papillomaviras infection in patients

目的：探讨壳聚糖碘治疗宫颈上皮内瘤变Ⅰ（CINⅠ）伴人乳头状瘤病毒（HPV）感染的临床疗效及安全性,为临床应用提供参考。方法：选取2014年10月~2015年6月科室确诊CINⅠ伴HPV感染的患者100例,随机分为治疗组和对照组,各50例,治疗组使用壳聚糖碘治疗,对照组未用药物治疗,观察治疗组的不良反应情况,对比两组患者治疗高危HPV感染转阴情况,所得数据采用SPSS16.0进行分析。结果：治疗组3个月及6个月HPV转阴率分别为74.0%、78.0%,对照组3个月及6个月HPV转阴率分别为48.0%、62.0%,差异有统计学意义（P〈0.05）,治疗组患者无严重不良反应发生。结论：壳聚糖碘治疗CIN1伴HPV感染疗效确切、不良反应小,值得临床推广应用。

Objective：To investigate clinical efficacy and safety of Chitosan-iodine in treatment of high-risk human papillomaviras infection in patients with cervical intraepithelial neoplasia Ⅰ（CIN Ⅰ）.Methods：A total of 100 patients diagnosed with CIN Ⅰ and cervical high-risk HPV infection during Oct.2014 to Jun.2015 were randomly divided into group treatment and group control with 50 cases in each group.Women of group treatment were received Chitosan-iodine,group control did not received any medication.The therapeutic results for high-risk HPV infection change to negative patients were compared between the two groups and adverse reactions were observed.Data obtained were analyzed using the software SPSS16.0.Results：The high-risk HPV infection change to negative rate were 74.0% within three month and 78.0% within six month respectively in group treatment,48.0% within three month and 62.0% within six month respectively in group control the difference was significant（P0.05）.There were no serious adverse reactions were observed in group treatment.Conclusion：Treatment of Chitosan-iodine for CIN Ⅰ with high-risk human papillomaviras infection in patients resulted in significant efficacy and few adverse reactions,which was worthy of clinical application.